Short answer
VHL genetic testing looks for inherited pathogenic variants in the VHL gene when von Hippel-Lindau syndrome is suspected. The question usually comes from a pattern of hemangioblastomas, clear cell kidney cancer at a young age, bilateral or multifocal renal tumors, pheochromocytoma or paraganglioma, pancreatic cysts or neuroendocrine tumors, endolymphatic sac tumors, or a family history of VHL-associated tumors.
When VHL testing usually fits
| Clue | Testing question | Why it matters |
|---|---|---|
| CNS or retinal hemangioblastoma | Should germline VHL testing be done? | A hereditary result can change surveillance for multiple organs and relatives. |
| Early, bilateral, or multifocal clear cell kidney cancer | Is this likely VHL or another hereditary renal syndrome? | Pattern and age guide which panel is most useful. |
| Pheochromocytoma or paraganglioma | Could VHL be part of a broader hereditary tumor panel? | Endocrine and renal findings often overlap with other syndromes. |
| Known family VHL variant | Should relatives have targeted testing? | Targeted testing is usually the clearest way to sort family risk. |
What the result can change
A pathogenic VHL result can change eye surveillance, brain and spine imaging, kidney screening, endocrine follow-up, pancreatic monitoring, and family cascade testing. Because VHL is a multisystem tumor syndrome, the result is less about naming one tumor and more about organizing a lifetime surveillance plan.
That is also why a deletion/duplication component can matter: a sequence-only test may miss a clinically important inherited variant.
Why negative or tumor-only results do not always settle the question
A negative result does not always rule out VHL if the phenotype is strong or if the assay did not include deletion and duplication analysis. Tumor-only VHL findings also need careful germline confirmation before family members are managed as if they are at risk.
The VHL gene is also involved in some sporadic kidney cancer biology, so the testing context matters: tumor-only biology is not the same thing as inherited family risk.
Questions to ask
- Was testing germline, tumor-only, or paired tumor-normal?
- Did the assay include both sequence analysis and deletion/duplication analysis?
- Which organs need surveillance if a pathogenic variant is found?
- Do relatives need targeted testing now, or only after genetics counseling?
- Could another hereditary renal or endocrine syndrome explain the pattern better?
What the result still cannot prove
A VHL result can clarify inherited risk, but it does not by itself predict every tumor, the timing of surveillance, or what a family member may eventually need.
FAQ
What does VHL genetic testing look for?
It looks for inherited pathogenic variants in the VHL gene that can explain a multisystem tumor syndrome affecting the brain, spine, retina, kidneys, adrenal glands, and pancreas.
Can a VHL result come from tumor testing only?
Yes. Tumor-only sequencing can show VHL changes, but that does not prove the change is inherited. Germline confirmation is needed if family risk is the question.
Does a negative result rule out VHL?
No. It can lower the chance, but it does not fully rule out VHL if the clinical pattern is strong or if deletion/duplication testing was missing.
Which tumors most often point toward VHL?
Retinal or CNS hemangioblastomas, early or multifocal clear cell kidney cancer, pheochromocytoma or paraganglioma, and some pancreatic lesions are classic clues.
Why does deletion/duplication testing matter?
Some clinically important VHL variants are larger than a simple sequence change, so a sequence-only test can miss them.
Why do family members need counseling?
If the variant is germline, relatives may need targeted testing and organ-specific screening that starts before symptoms appear.
Related guides: hereditary cancer genetic testing, hereditary kidney disease genetic testing, RET vs VHL pheochromocytoma genetic testing, and tumor genomic versus inherited testing.